Durvalumab (anti-PD-L1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to B7-H1 / PD-L1 / CD274, >95%, high purity, Human IgG1, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefits
  • Host species: Human
  • Species reactivity(Reacts with): Cynomolgus monkey,Human,Mouse
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
Item Number
D412005
Grouped product items
SKUSizeAvailabilityPrice Qty
D412005-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$39.90
D412005-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$159.90
D412005-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$664.90
D412005-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,196.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<0.01EU/μg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameDurvalumab (anti-PD-L1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to B7-H1 / PD-L1 / CD274, >95%, high purity, Human IgG1
Specifications & PurityExactAb™, Validated, Carrier Free, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host speciesHuman
SpecificityB7-H1 / PD-L1 / CD274
ApplicationELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of Programmed cell death 1 ligand 1 inhibitor
Product Description

Durvalumab is an humanized anti-PD-L1 monoclonal antibody, completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
Purity>95% (SDS-PAGE&SEC)
Endotoxin Level<0.01EU/μg

Product Properties

Antibody TypePrimary antibody
ClonalityRecombinant
IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE26.5 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 180.0 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
SourceCHO supernatant
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1428935-60-7

Images

Durvalumab (anti-PD-L1) (D412005) - Flow Cytometry
Flow Cytometry analysis of PBMC cells labelling PD-L1 (red) with Durvalumab (anti-PD-L1) (D412005) . Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Durvalumab (anti-PD-L1) (D412005) - SEC
The purity of Durvalumab (anti-PD-L1) (D412005) is more than 95% verified by HPLC.

Associated Targets(Human)

CD274 Tclin Programmed cell death 1 ligand 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0404206Certificate of AnalysisApr 08, 2024 D412005
ZJ24F0404207Certificate of AnalysisApr 08, 2024 D412005
ZJ24F0404208Certificate of AnalysisApr 08, 2024 D412005

Related Documents

References

1. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS.  (2017)  Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab..  Sci Rep,  (1): (5532).  [PMID:28717238] [10.1021/op500134e]

Solution Calculators